Skip to main content
. 2017 Jun 14;8(4):851–861. doi: 10.1007/s13300-017-0279-y

Fig. 2.

Fig. 2

Abdominal visceral fat area (VFA) and subcutaneous fat area (SFA) at baseline and at 12 weeks after the administration of ipraglifrozin. Data are presented as the median with interquartile range